Premium
Clinical Value of a Dopaminergic Agonist Administration in Migraine Patients
Author(s) -
Geraud G.,
Guell A.,
Courtade M.,
Dupui Ph.,
Bes A.
Publication year - 1983
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1983.hed2304191.x
Subject(s) - migraine , medicine , dopaminergic , anesthesia , cephalalgia , nausea , vomiting , agonist , headaches , dopamine , surgery , receptor
SYNOPSIS The migraine subject exhibits a dopaminergic vascular hypersensitivity on the brain level (CBF increase) as well as on the peripheral level (BP decrease). A dopaminergic agonist, piribedil, was administered by intravenous infusion (0,1 mg/kg over 30 minutes) to 150 patients known to suffer from migraine or other kinds of headache. 94% of migraine patients developed nausea or vomiting and 69% a decrease of BP, severe enough to discontinue the infusion. In non migraine headaches, the piribedil infusion had no effects in 61% of patients and provoked a decrease of BP in 16% of cases only. The piribedil test could be used to distinguish genuine migraine from other cephalalgia in patients prone to headache.